C78.00: Secondary malignant neoplasm of unspecified lung

C78.00, secondary malignant neoplasm of unspecified lung, is listed as a covered diagnosis in 5 Medicare billing and coding articles that apply to 38 HCPCS Level II codes, including Q2043 (Sipuleucel-t, minimum of 50 million autologous cd54+ cells…), J9217 (Leuprolide acetate (for depot suspension), 7.5 mg), J1952 (Leuprolide injectable, camcevi, 1 mg). The articles come from 4 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.

HCPCS Level II codes with C78.00 as a covered diagnosis

CodeDescriptionMedicare coverageDMEPOS fee 2026 (state range)Articles listing it
Q2043Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusionSpecial coverage instructions apply—1
J9217Leuprolide acetate (for depot suspension), 7.5 mgSpecial coverage instructions apply—1
J1952Leuprolide injectable, camcevi, 1 mgCarrier judgment—1
J3315Injection, triptorelin pamoate, 3.75 mgSpecial coverage instructions apply—1
J1954Injection, leuprolide acetate for depot suspension (lutrate depot), 7.5 mgCarrier judgment—1
J9202Goserelin acetate implant, per 3.6 mgSpecial coverage instructions apply—1
J1950Injection, leuprolide acetate (for depot suspension), per 3.75 mgSpecial coverage instructions apply—1
J3316Injection, triptorelin, extended-release, 3.75 mgSpecial coverage instructions apply—1
J9218Leuprolide acetate, per 1 mgSpecial coverage instructions apply—1
J9219Leuprolide acetate implant, 65 mgSpecial coverage instructions apply—1
J9225Histrelin implant (vantas), 50 mgSpecial coverage instructions apply—1
G0340Image-guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum five sessions per course of treatmentCarrier judgment—1
G0339Image-guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatmentCarrier judgment—1
G0563Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and real-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractionsCarrier judgment—1
J8999Prescription drug, oral, chemotherapeutic, nosSpecial coverage instructions apply—1
Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day periodSpecial coverage instructions apply—1
Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodSpecial coverage instructions apply—1
J8530Cyclophosphamide; oral, 25 mgSpecial coverage instructions apply—1
J8597Antiemetic drug, oral, not otherwise specifiedSpecial coverage instructions apply—1
J8610Methotrexate; oral, 2.5 mgSpecial coverage instructions apply—1
J8498Antiemetic drug, rectal/suppository, not otherwise specifiedSpecial coverage instructions apply—1
Q5110Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgramSpecial coverage instructions apply—1
Q5125Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgramCarrier judgment—1
Q5101Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgramSpecial coverage instructions apply—1
J1442Injection, filgrastim (g-csf), excludes biosimilars, 1 microgramSpecial coverage instructions apply—1

13 more codes are listed. See every code with payment by region in Caduvo.

Medicare policy articles listing C78.00

A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.

Other C78 diagnoses (Secondary malignant neoplasm of respiratory and digestive organs)

Frequently asked questions

Does Medicare cover C78.00 (Secondary malignant neoplasm of unspecified lung)?

Medicare covers items and services, not diagnoses. 5 Medicare billing and coding articles list C78.00 as a covered diagnosis for 38 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.

Which HCPCS codes can be billed with ICD-10 C78.00?

The Level II codes from the policies most specific to this diagnosis are Q2043 (Sipuleucel-t, minimum of 50 million autologous cd54+ cells…, 1 article); J9217 (Leuprolide acetate (for depot suspension), 7.5 mg, 1 article); J1952 (Leuprolide injectable, camcevi, 1 mg, 1 article); J3315 (Injection, triptorelin pamoate, 3.75 mg, 1 article); J1954 (Injection, leuprolide acetate for depot suspension…, 1 article). Code choice depends on the item supplied; check each code's descriptor.

Which Medicare policy articles list C78.00?

A55719 (Sipuleucel-T (Provenge®) - Coverage Criteria for Prostate Cancer – Clarification); A52453 (Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs); A56874 (Billing and Coding: Stereotactic Radiation Therapy: Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT)), and 2 more articles.

What is ICD-10-CM code C78.00?

C78.00 is the ICD-10-CM code for secondary malignant neoplasm of unspecified lung, in category C78 (Secondary malignant neoplasm of respiratory and digestive organs), chapter 2: Neoplasms.

Next steps

Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.

Chapter 2: Neoplasms · All diagnoses · HCPCS lookup